Berinert (C1 esterase inhibitor [human])

Berinert is covered for FDA‑approved treatment of acute HAE attacks and compendial prophylaxis in patients with HAE type I or II due to C1‑INH deficiency (HAE with normal C1‑INH or other causes not covered). Coverage requires baseline labs showing functional C1‑INH <50% and low serum C4, prescription or consultation by an HAE specialist/allergist‑immunologist, dosing limited to 20 IU/kg IV no more than once daily, 12‑month authorizations, and reauthorization with documented clinical benefit (reduced attack frequency, severity, duration, or rapid symptom relief).

"Treatment of acute attacks of Hereditary Angioedema (HAE)."

Sign up to see full coverage criteria, indications, and limitations.